Clinical Trials
2
Active:2
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Study of Tamibarotene in Patients With ADPKD
Phase 2
Active, not recruiting
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Rege Nephro Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06289998
- Locations
- 🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇯🇵Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan
News
Rege Nephro Secures $150 Million in Series B Funding to Advance Kidney Disease Therapies
Rege Nephro has successfully raised $22.5 billion yen ($150 million) in Series B funding to advance clinical trials for kidney disease therapies.